M. Alexander Otto began his reporting career early in 1999 covering the pharmaceutical industry for a national pharmacists' magazine and freelancing for the Washington Post and other newspapers. He then joined BNA, now part of Bloomberg News, covering health law and the protection of people and animals in medical research. Alex next worked for the McClatchy Company. Based on his work, Alex won a year-long Knight Science Journalism Fellowship to MIT in 2008-2009. He joined the company shortly thereafter. Alex has a newspaper journalism degree from Syracuse (N.Y.) University and a master's degree in medical science -- a physician assistant degree -- from George Washington University. Alex is based in Seattle.
News
Age should not be a barrier to aggressive esophageal cancer treatment
Comorbidities, fitness are what matters.
News
RPLND deemed ‘attractive’ option for early metastatic seminoma
The 2-year recurrence-free survival rate was 84% in a phase 2 trial.
News
CCR score can guide treatment decisions after radiation in prostate cancer
The score can identify patients with a low risk of metastasis who could potentially skip androgen deprivation therapy.
News
Cemiplimab approved for locally advanced, metastatic basal cell carcinoma
The approval is based on phase 2 trial results.
News
TBI beats chemoconditioning for ALL transplants in children
Total body irradiation plus etoposide remains the conditioning regimen of choice.
News
New technique uses voice to evaluate thyroid nodules
An investigational technique could improve tumor detection.
News
Tool predicts severe toxicity from chemo in older breast cancer patients
The new scoring system outperformed existing tools.
Article
Color-imaging endoscopy improves detection of upper GI cancer
Neoplastic lesions were detected in 60 patients (8%) with LCI versus 36 patients (4.8%) with WLI, which translated to a 1.67 times higher rate of...
News
Caregiver burden of outpatient ASCT for multiple myeloma comparable with inpatient transplant
But only if caregivers are equipped for outpatient care.
News
Cost is the main hurdle to broad use of caplacizumab for TTP
“If we take finances out, I think almost every patient except those with a bleeding risk or bleeding problem should get it,” an investigator said...